bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Large Decrease in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 40,326 shares, a decline of 22.4% from the December 31st total of 51,967 shares. Based on an average daily volume of 73,792 shares, the short-interest ratio is presently 0.5 days. Currently, 0.9% of the company’s shares are short sold. Currently, 0.9% of the company’s shares are short sold. Based on an average daily volume of 73,792 shares, the short-interest ratio is presently 0.5 days.

Institutional Investors Weigh In On bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Scientech Research LLC acquired a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 16,583 shares of the company’s stock, valued at approximately $49,000. Scientech Research LLC owned about 0.46% of bioAffinity Technologies as of its most recent SEC filing. 1.64% of the stock is currently owned by institutional investors.

bioAffinity Technologies Stock Down 13.8%

bioAffinity Technologies stock traded down $0.18 during trading hours on Tuesday, reaching $1.10. The stock had a trading volume of 38,143 shares, compared to its average volume of 81,001. bioAffinity Technologies has a 52 week low of $0.99 and a 52 week high of $46.53. The business’s 50 day moving average price is $1.35 and its 200-day moving average price is $3.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.65 and a quick ratio of 3.64. The company has a market cap of $4.93 million, a price-to-earnings ratio of -0.05 and a beta of 2.44.

bioAffinity Technologies (NASDAQ:BIAF) last announced its earnings results on Friday, November 14th. The company reported ($2.70) earnings per share for the quarter, meeting the consensus estimate of ($2.70). bioAffinity Technologies had a negative net margin of 217.45% and a negative return on equity of 425.87%. The company had revenue of $1.45 million during the quarter, compared to the consensus estimate of $1.41 million.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, bioAffinity Technologies currently has a consensus rating of “Reduce”.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.